<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438461</url>
  </required_header>
  <id_info>
    <org_study_id>CR108446</org_study_id>
    <secondary_id>42847922MDD1004</secondary_id>
    <nct_id>NCT03438461</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 6-Period, 8-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Subjects Under Fasted and Semi-fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the pharmacokinetics (PK) and relative
      oral bioavailability of 3 oral tablet formulations of seltorexant in fasted and semi-fasted
      conditions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) when Compared for 3 Oral Tablet Formulations of Seltorexant</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>Cmax is the maximum observed plasma concentration and will be evaluated when compared for 3 oral tablet formulations of seltorexant in fasted and semi-fasted conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from the Time of Study Drug Administration to the Last Measurable Plasma Concentration (AUC[0‐last]) when Compared for 3 Oral Tablet Formulations of Seltorexant</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>AUC (0‐last) is the area under the plasma concentration‐time curve from the time of study drug administration to the last measurable plasma concentration and will be evaluated when compared for 3 oral tablet formulations of seltorexant in fasted and semi-fasted conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve Extrapolated to Infinite Time (AUC[0-infinity]) when Compared for 3 Oral Tablet Formulations of Seltorexant</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>AUC (0‐infinity) is the is the area under the plasma concentration‐time curve from time zero to infinite time, calculated using the observed value of the last non-zero plasma concentration and will be evaluated when compared for 3 oral tablet formulations of seltorexant in fasted and semi-fasted conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability of Seltorexant when Compared for 3 Oral Tablet Formulations of Seltorexant</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>Relative bioavailability is the percentage of the administered dose that is systemically available, calculated as: (AUC [0-infinity] of test divided by AUC [0-infinity] of reference) multiplied by 100, where the reference treatment is a non-intravenous administration. Relative bioavailability will be evaluated when compared for 3 oral tablet formulations of seltorexant in fasted and semi-fasted conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax when Compared Between Fasted and Semi-Fasted Conditions</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>Cmax when compared between fasted and semi-fasted conditions will be evaluated for the 3 oral tablet formulations of seltorexant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0‐last) when Compared Between Fasted and Semi-Fasted Conditions</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>AUC (0‐last) when compared between fasted and semi-fasted conditions will be evaluated for the 3 oral tablet formulations of seltorexant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0‐infinity) when Compared Between Fasted and Semi-Fasted Conditions</measure>
    <time_frame>Predose, 20 minutes (min), 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 20h (Day 1), 24h, 36h (Day 2), 48h (Day 3) postdose</time_frame>
    <description>AUC (0‐infinity) when compared between fasted and semi-fasted conditions will be evaluated for the 3 oral tablet formulations of seltorexant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From Screening till End-of- Study (up to approximately 18 weeks)</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seltorexant 40 mg</intervention_name>
    <description>Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seltorexant 20 mg</intervention_name>
    <description>Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.</description>
    <arm_group_label>Part 2 (Optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have signed an informed consent form (ICF) indicating they understand the purpose of
             and procedures required for the study and are willing to participate in the study

          -  Willing to adhere to the prohibitions and restrictions specified in the study protocol

          -  If a woman of childbearing potential, must have a negative serum beta-human chorionic
             gonadotropin (beta-hCG) pregnancy test at screening and a negative urine pregnancy
             test on Day -1 of the first treatment period

          -  If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for at least 30 days after the last study drug
             administration

          -  A man, who is sexually active with a woman of childbearing potential and has not had a
             vasectomy, must agree to use an adequate contraception method as deemed appropriate by
             the investigator (example, vasectomy, double-barrier, partner using effective
             contraception) and to not donate sperm during the study and for 3 months after
             receiving the last dose of study drug

        Exclusion Criteria:

          -  Has a history of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid
             abnormalities, significant pulmonary disease, including bronchospastic respiratory
             disease, diabetes mellitus, hepatic (Child-Pugh Score greater than or equal to [&gt;=] 7)
             or renal insufficiency (estimated glomerular filtration rate [eGFR] less than (&lt;) 60
             milliliter per minute per 1.73 meter square (mL/min/1.73m^2) based on the modified
             diet renal disease [MDRD] formula determined at screening, thyroid disease, neurologic
             (including seizure disorders) or psychiatric disease, infection, or any other illness
             that the investigator considers should exclude the participant or that could interfere
             with the interpretation of the study results. Significant gastrointestinal past
             history, or any disease/surgery (excluding cholecystectomy and appendectomy) that
             would interfere with drug absorption

          -  Has clinically significant abnormal values for hematology, serum chemistry (including
             thyroid stimulating hormone [TSH] at screening only) or urinalysis at screening or at
             admission to the study site. It is expected that laboratory values will generally be
             within the normal range for the laboratory, though minor deviations, which are not
             considered to be of clinical significance to both the investigator and to the Janssen
             Research &amp; Development Safety Physician, are acceptable

          -  Has clinically significant abnormal physical examination, vital signs, or 12 lead
             electrocardiogram (ECG) at screening or at admission to the study site as deemed
             appropriate by the investigator

          -  Has used any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for paracetamol (acetaminophen), oral contraceptives, and
             hormonal replacement therapy within 14 days before the first dose of the study drug is
             scheduled or has used any systemic herbal medications or dietary supplements including
             products containing Hypericum perforatum (example, St. John's Wort) from 21 days
             before the first dose of study drug is scheduled

          -  Received a known inhibitor of CYP(cytochrome P450)3A4 or CYP2C9 activity within 14
             days or a period less than 5 times the drugs half-life; whichever is longer, before
             the first dose of the study drug is scheduled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRAHS</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108446</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

